<code id='FF7258C12F'></code><style id='FF7258C12F'></style>
    • <acronym id='FF7258C12F'></acronym>
      <center id='FF7258C12F'><center id='FF7258C12F'><tfoot id='FF7258C12F'></tfoot></center><abbr id='FF7258C12F'><dir id='FF7258C12F'><tfoot id='FF7258C12F'></tfoot><noframes id='FF7258C12F'>

    • <optgroup id='FF7258C12F'><strike id='FF7258C12F'><sup id='FF7258C12F'></sup></strike><code id='FF7258C12F'></code></optgroup>
        1. <b id='FF7258C12F'><label id='FF7258C12F'><select id='FF7258C12F'><dt id='FF7258C12F'><span id='FF7258C12F'></span></dt></select></label></b><u id='FF7258C12F'></u>
          <i id='FF7258C12F'><strike id='FF7258C12F'><tt id='FF7258C12F'><pre id='FF7258C12F'></pre></tt></strike></i>

          leisure time

          leisure time

          author:knowledge    Page View:2283
          Stock Market
          APStock

          Introducing STAT’s Biotech Q2 Scorecard, our emoji-enabled means of tracking 12 make-or-break events expected over the next three months.

          When each clinical trial or FDA decision crosses the wires, we’ll add in the appropriate rocket ship, grimace face, bulging bicep or broken heart — whatever captures the mood.

          advertisement

          Read on for brief explanations of what we’re watching for from each company.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more
          STAT Summit: Michael J. Fox on progress in Parkinson's research
          STAT Summit: Michael J. Fox on progress in Parkinson's research

          STATWhenMichaelJ.FoxwasdiagnosedwithParkinson’sdiseaseatage29,hisclearestsymptomwasasmallone—hispink

          read more
          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more

          GSK’s asthma push continues as drug succeeds in Phase 3 trials

          AkiraSuemori/APAnewasthmatreatmentthatcouldbeadministeredjustonceeverysixmonthshassucceededintwoPhas